Table 4.

Concordant questionnaires that contained no indicators for face-to-face review stratified by treatment pathway (N=90).

Treatment pathway (number of patients)	Concordant questionnaires per pathway without indicators for FTFa review, n (%)
Immunotherapy (n=10)	7 (70)
Lung SABRb (n=6)	3 (50)
Abiraterone and enzalutamide (n=10)	4 (40)
Pazopanib (n=10)	4 (40)
Imatinib (n=8)	3 (38)
Breast RTc (n=10)	3 (30)
Prostate RT (n=10)	1 (10)
Colorectal chemotherapy (n=11)	1 (9)
Head and neck RT (n=10)	0 (0)
Prostate chemotherapy (n=5)	0 (0)

^aFTF: face-to-face.

^bSABR: stereotactic ablative radiotherapy.

^cRT: radiotherapy.